Online inquiry

IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12834MR)

This product GTTS-WQ12834MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FZD10 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_007197.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 11211
UniProt ID Q9ULW2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12834MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8598MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ15358MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ12368MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ14641MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ10930MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ12220MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ14012MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ3004MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Angiocept
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW